ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Carcinoma
Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Lung Cancer
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Hanyang, Seoul, KOR:

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

as neoaduvant treatment in resectable or borderline resectable pancreatic cancer is feasible and efficacious.The combination of Dur...

Active, not recruiting
Pancreatic Cancer
Drug: Durvalumab
Drug: Gemcitabine

Phase 2

Do-Youn Oh

Seoul, Korea, Republic of

Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival rate has shown less than 10% ...

Active, not recruiting
Pancreatic Cancer
Drug: Chlorphenesin Carbamate, Hydroxychloroquine

Phase 1

Changhoon Yoo

Seoul, Seoul, South Korea

Antroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinon ...

Active, not recruiting
Pancreatic Neoplasm
Drug: Antroquinonol

Phase 1, Phase 2

Golden Biotechnology

Seoul, Korea, Republic of and 8 other locations

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: nab-paclitaxel
Drug: gemcitabine

Phase 2

Astellas
Astellas

Seoul, Korea, Republic of and 135 other locations

to therapy in first-line patients with unresectable or metastatic pancreatic cancer.Part A is a phase 1b dose-escalation design tha...

Enrolling
Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Drug: AMP945 ascending doses
Drug: AMP945 RP2D

Phase 1, Phase 2

Amplia Therapeutics

Seoul, Korea, Republic of and 12 other locations

combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic...

Enrolling
Pancreatic Ductal Adenocarcinoma
Drug: modified FOLFIRINOX
Drug: Gemcitabine-nab-paclitaxel

Phase 1

Onconic Therapeutics

Seoul, Korea, Republic of

of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic...

Enrolling
Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Immuncell-LC

Phase 3

GC Cell

Seoul, Daehak-ro, Jongno-gu, Korea, Republic of

or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have recei...

Enrolling
Pancreatic Cancer Metastatic
Pancreatic Cancer Stage IV
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 2, Phase 3

Panbela Therapeutics

Seoul, Seoul Teugbyeolsi, Korea, Republic of and 91 other locations

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor...

Active, not recruiting
Pancreatic Adenocarcinoma
Drug: Gemcitabine
Drug: Bevacizumab

Phase 1, Phase 2

Roche
Roche

Seoul, Korea, Republic of and 26 other locations

a Day on Days 1 to 5, Days 8 to 12 and Days 15 to 19 Along with Abraxane Plus Gemcitabine in Patients with Metastatic Adenocarcinoma of the Pancreas...

Enrolling
Metastatic Adenocarcinoma of the Pancreas
Combination Product: Minnelide

Phase 1

Minneamrita Therapeutics

Soeul, Korea, Republic of

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems